Locke J. Bryan

745 total citations
47 papers, 450 citations indexed

About

Locke J. Bryan is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Locke J. Bryan has authored 47 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 17 papers in Pathology and Forensic Medicine and 13 papers in Genetics. Recurrent topics in Locke J. Bryan's work include Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Immune Cell Function and Interaction (8 papers). Locke J. Bryan is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Immune Cell Function and Interaction (8 papers). Locke J. Bryan collaborates with scholars based in United States, Georgia and France. Locke J. Bryan's co-authors include Leo I. Gordon, V. Gregory Chinchar, Scott Long, Gang Zhou, Zhi‐Chun Ding, Tingting Chen, Tsadik Habtetsion, Michal Kuczma, Zhonglin Hao and Neil A. Zakai and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Locke J. Bryan

34 papers receiving 443 citations

Peers

Countries citing papers authored by Locke J. Bryan

Since Specialization

Citations

This map shows the geographic impact of Locke J. Bryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Locke J. Bryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Locke J. Bryan more than expected).

Fields of papers citing papers by Locke J. Bryan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Locke J. Bryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Locke J. Bryan. The network helps show where Locke J. Bryan may publish in the future.

Co-authorship network of co-authors of Locke J. Bryan

This figure shows the co-authorship network connecting the top 25 collaborators of Locke J. Bryan. A scholar is included among the top collaborators of Locke J. Bryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Locke J. Bryan. Locke J. Bryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality 2025 ·JAMA Oncology ·(unknown), Sandra J. Lee, Jessica K. Altman, Selina M. Luger, (unknown), James M. Foran, (unknown), Lisa Y. Law, Locke J. Bryan, (unknown), Kebede H. Begna, Alexander E. Perl, Joseph Vadakara, Rubina Qamar, Raymond C. Bergan, Michael Fisch, Ruth C. Carlos, Lynne I. Wagner, Vamsi Kota, Mark R. Litzow	2
2	SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma 2025 ·PubMed ·Nilanjan Ghosh, (unknown), (unknown), Adam J. Olszewski, Locke J. Bryan, Alexey V. Danilov, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg	0
3	ENCEPHALOPATHY FROM DELAYED METHOTREXATE CLEARANCE DUE TO LOCULATED PARAPNEUMONIC PLEURAL EFFUSION IN CNS LYMPHOMA 2024 ·CHEST Journal ·S.G. Smith, (unknown), (unknown), Mohammad Azam, (unknown), (unknown), Locke J. Bryan, (unknown)	0
4	Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost 2024 ·Blood ·(unknown), Mahran Shoukier, (unknown), (unknown), (unknown), (unknown), Vamsi Kota, Locke J. Bryan, Jörge E. Cortes	0
5	Allogeneic Stem Cell Transplantation for High-Risk Multiple Myeloma 2024 ·Blood ·(unknown), (unknown), (unknown), (unknown), Locke J. Bryan, (unknown), Anand Jillella, Vamsi Kota, Jörge E. Cortes	0
6	Single center experience of using Anakinra prophylactically at Day 0 to reduce CD19 CART toxicities. 2023 ·Journal of Clinical Oncology ·(unknown), Rishabh Singh, (unknown), (unknown), Michal Kubiak, (unknown), (unknown), (unknown), Mohammad Mian, (unknown), (unknown), Locke J. Bryan, Anand P. Jillella, Vamsi Kota	0
7	Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma 2023 ·JAMA Oncology ·Locke J. Bryan, Carla Casulo, Pamela B. Allen, Scott E. Smith, Hatice Savas, Gary Dillehay, Reem Karmali, Barbara Pro, (unknown), Latifa A. Bazzi, Joan S. Chmiel, (unknown), Jayesh Mehta, Leo I. Gordon, Jane N. Winter	29
8	Bortezomib Induced Peripheral and Severe Autonomic Neuropathy Characterized By Dizziness, Orthostatic Hypotension and Weight Loss 2023 ·Blood ·(unknown), (unknown), (unknown), Courtney D. Corley, Kimberly Green, (unknown), (unknown), Locke J. Bryan, (unknown), (unknown), (unknown), Mohammad Mian, Ravindra Kolhe, Vamsi Kota, Anand Jillella	0
9	Academic Outreach and Collaboration with Community Oncology Practices to Enhance Referrals and Reduce Disparities in Hematological Malignancies 2023 ·Blood ·Vamsi Kota, (unknown), (unknown), Mohammad Mian, (unknown), Courtney D. Corley, (unknown), (unknown), (unknown), (unknown), Kimberly Green, (unknown), (unknown), Locke J. Bryan, Jörge E. Cortes, Anand Jillella	1
10	Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy 2022 ·Journal for ImmunoTherapy of Cancer ·Nada S. Aboelella, (unknown), (unknown), (unknown), Zhi‐Chun Ding, Hongyan Xu, Gregory S. Gorman, Roni J. Bollag, Marco L. Davila, Locke J. Bryan, David H. Munn, Gary A. Piazza, Gang Zhou	10
11	Update on the role of copanlisib in hematologic malignancies 2021 ·Therapeutic Advances in Hematology ·(unknown), (unknown), Locke J. Bryan	11
12	Leukaemic relapse of anaplastic large cell lymphoma, ALK negative 2021 ·BMJ Case Reports ·(unknown), (unknown), Natasha M. Savage, Locke J. Bryan	3
13	Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate 2020 ·Supportive Care in Cancer ·Amber B. Clemmons, (unknown), (unknown), Jennifer L. Waller, (unknown), Locke J. Bryan	5
14	A 43-Year-Old Woman With Hoarseness of Voice and Chest Pressure 2019 ·CHEST Journal ·(unknown), Thomas A. Dillard, Locke J. Bryan	0
15	Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells 2017 ·Scientific Reports ·Zhi‐Chun Ding, Tsadik Habtetsion, Yang Cao, Tao Li, Chufeng Liu, Michal Kuczma, Tingting Chen, Zhonglin Hao, Locke J. Bryan, David H. Munn, Gang Zhou	22
16	Persistent indolent pancolonic marginal zone lymphoma of MALT-type with plasmacytic differentiation – A rare post-transplant lymphoma? 2017 ·Human Pathology Case Reports ·(unknown), Natasha M. Savage, Suash Sharma, Locke J. Bryan, Mark Raffeld, Elaine S. Jaffe	4
17	Pidilizumab in the treatment of diffuse large B-cell lymphoma 2014 ·Expert Opinion on Biological Therapy ·Locke J. Bryan, Leo I. Gordon	18
18	Higher soluble P-selectin is associated with chronic venous insufficiency: The San Diego Population Study 2012 ·Thrombosis Research ·Locke J. Bryan, Peter Callas, Michael H. Criqui, Mary Cushman	8
19	Why is My Patient Anemic? 2012 ·Hematology/Oncology Clinics of North America ·Locke J. Bryan, Neil A. Zakai	11
20	Induction of apoptosis in frog virus 3-infected cells 2003 ·Virology ·V. Gregory Chinchar, Locke J. Bryan, (unknown), Scott Long, (unknown)	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact